Medical network on March 6 - March 4, by the China association of pharmaceutical enterprise management and other 25 Chinese medicine industry association (learn) will be the host of the 2017 the ninth "sound, responsibility" the industry of the National People's Congress on behalf of the Chinese people's political consultative conference committee symposium held in Beijing, from more than 40 pharmaceutical industry to the National People's Congress, CPPCC member to attend the discussion; State department, health department, the national development and reform commission, planning commission, people club department, the ministry, the ministry of commerce, ministry of finance, the state food and drug safety administration of the national bureau of traditional Chinese medicine and other medical related government department leaders and experts were invited to attend the meeting.
In policy increased in 2016 and the New Deal at the beginning of 2017, China's pharmaceutical industry is undergoing profound fission and reform, the next step of reform, how to drug prices and material price, consistency problem such as evaluation, professional medical representatives will affect how pharmaceutical enterprises and in each individual, around the many hot topics of the industry, let's listen to how to say on behalf of the members.
▍ focus one: API price increases
Deputy to the National People's Congress, henan LingRui group chairman Xiong Weizheng:
API irrational price now, I think is too ridiculous. Turned out to be 150 yuan a kilogram now up to 980, through investigation we found many problems, have a plenty of because of raw materials raw material review current regulators take approval, the approval to production, can't not approved production; Have a plenty of because dealers push up prices, this phenomenon is very serious in our country at present, many enterprises, many bosses told me this thing, some common medicine raw materials prices lead to a lot of enterprise can't production, still more serious situation, to draw the attention of the authorities.
To solve this problem is not difficult, my advice is to let go of drug production, access for API production manufacturers, a filing system, does not need all of the raw materials have to take approval, this also is not in conformity with the current situation. At the same time, more important is our price of the commodity price departments should strengthen supervision, so as to ensure the safety of the drug from the each link.
The National People's Congress, sichuan good doctor pharmaceutical group co., LTD., chairman of the board of directors GengFu can:
After market research, we found that since the state of drug prices, some drug prices, including drug prices due to raw material monopoly is one of the main factors. Among them, there are two kinds of situations, one is the document number less active pharmaceutical ingredients; The second is part of Chinese traditional medicine extract, Chinese medicine yinpian, pharmaceutical excipients shouldn't post wrong sent a document number.
In view of the above API monopoly behavior, in the hope that relevant departments in accordance with the law sanctions monopoly monopoly regulation, guarantee the healthy development of the pharmaceutical industry, safeguard the people can really "coercing disease, affordable medicine". At the same time, the enterprise also to self-discipline, not monopoly, abide by the law, is committed to research and development innovation, do law-abiding enterprises.
Suggestion: first, improve and implement the anti-monopoly law, formulate the act of the windfall profits; Second, cleaning and immediately cancel the approval number of traditional Chinese medicine (natural medicine) extract and banned; Third, on the part of the API to implement price intervention (such as: the government pricing) and production tasks; Fourth, set up to encourage API registration access system.
The National People's Congress chairman of the board of directors of the company and shandong xin pharmaceutical co., LTD Du Zhenxin
With the development of the pharmaceutical industry, medicinal API registration management, the disadvantages of emerging medicinal material to establish a scientific and efficient management system, and Suggestions on the basis of the advanced experience of developed countries, medicinal raw materials for the record management system, establish and perfect the system of DMF.
DMF is refers to the medicinal materials production enterprises, in accordance with the prescribed procedures, the production process, quality standards, all technical data, process parameters and quality indexes such as voluntarily submit to the CFDA, for the pharmaceutical production enterprise in the drug registration, supervision and administration department and supervision and use of technical documents of production management system. Voluntary principle is submitted and technical data are divided into the nature of public and private parts, review and approval, the authorization to use, change to update and so on. Management style is the applicant all the relevant information to the drug regulatory agency of the initiative register put on record, the public part of the information for the use of preparations when companies choose, non-public part information in preparation for drug regulatory department for examination and approval and production companies to check.
The National People's Congress, zhejiang kahn the group's chairman Hu Jijiang:
Not to cut approval is not batch of API, API monopoly make us very uncomfortable, now rise 20 times, 30 times or even 100 times to get our own can't production, but the examination and approval and was very hard, try not to, this is also the market behavior. I am still that sentence, the market can tube to tube to the market, the you tube you tube, tube should be enterprise on other things.
▍ focus 2:800000 pharmacist legislation
The CPPCC national committee, Pfizer China corporate affairs director danlong feng presented made:
Should attach great importance to the legislative process of casting and accelerate drug, in January of this year the state council general office on the drug circulation system reform related documents, points out that should actively play a role of pharmacists, to carry out the pharmacist rights and responsibilities, and give full play to the pharmacist in the use of prescription of the role.
Pharmacist law in legislative work plan in 2016 under the state council as a program of study, by the national health development planning commission and drafting, in accordance with the normal legislative process takes a few years, now there are about more than 80 pharmacists in China, their role is very big, but there is no, can't can depend on. Stable pharmacist team, protection and use of drugs and drug safety of the people is urgently needed, it is recommended that accelerate the formulated and promulgated the pharmacist law of the People's Republic of China, formulate unified pharmacist system and access performance, clarify the legal status of pharmacists and has, guarantee and the use of drugs, drug safety maintenance.
The National People's Congress, kahn pharmaceutical chairman Hu Jijiang:
Now, doctors have medical act, a method of traditional Chinese medicine of traditional Chinese medicine, so far we don't have a pharmacist law, management state drugstore pharmacist now, factory need medicine, medicine circulation enterprises need, but there is no medicine clinics, clinics in medicine, hospital medicine, only a few percent, the proportion of the hospital and medical institutions as long as the medicine must be there should be a pharmacist in theory, but now the occupational pharmacist is not a law, tube is less than the health sector, a system in China should be all of the same nature, how can just medicine end whether medical head it? Pharmacist law is necessary to start from this Angle, how should be beneficial to the industry at the same time in the Internet age, from the perspective of industry to develop medicine method, pharmacist law is necessary.
▍ focus 3: professional medical representatives
The CPPCC national committee, Pfizer China corporate affairs director danlong feng presented made:
In 2015 there was a proposal is to strengthen the management of medical representative be included in the professional proposal, in 2015 by the national medical representatives in the classification of the People's Republic of China red point, become a formal professional, this is countries an important measure to promote professional norms. Recently the 13th it under the state council to speed up the management of medical representative, build system of medical representative register put on record, it is pointed out the direction for standard management. Reasonable medical representative is related to drug safe use, also is related to the patient's health and life safety, so you should as early as possible in its list of national vocational qualifications directory, set up perfect professional standard and national professional management system to regulate the employees, so as to make a medical representative real engaged in drug information, communication, feedback of professionals.
▍ focus 4: hierarchical diagnosis and treatment, free practice
The CPPCC national committee, the Beijing university first hospital heart and heart with the director of the center Blood:
We push in grading diagnosis and country policy in the process of the doctor can do, for high quality human resources integration, how to develop human resources market pattern, the doctor group is an important form.
Today I have a proposal to emphasize from establishing the doctor group to push the grading and communities in diagnosis and treatment, the objective should be a polite, more important is through the doctor group set up, how to build their own standard, make the medicine more standardized process, doctors do a doctor, the doctor not to do the doctor not to do.
In addition more emphasis by the doctor group social form, is the pattern of social market-oriented, to conduct the high quality resources of doctors to the county hospital grading diagnosis and treatment, countries should formulate corresponding management measures, should give a lot of policy support, there should be some management standards, so that to make this work really able to promote orderly, I'm sure I will work for our country the whole medical system.
▍ focus five: hospital prescription outflow
The National People's Congress, hunan people big pharmacy chairman Xie Zilong:
Three proposal for information sharing to promote hospital prescription outflow, I raised three times, the health development planning commission grassroots medical department told me that every time need money, did it take so much money. For this thing I specifically got a deputy minister of the ministry of finance, really hard to solve this problem. I recently to wuzhen Internet hospital, to a few places in the United States, I suddenly found a feeling, actually don't need the money to build such a platform, why don't need the money? On the one hand, it is whether the hospital each of our enterprise, the functional departments, enterprises, itself has the information system, we only need a certain functional departments to develop a standard.
In addition, the last time I communicate with Internet wuzhen, chairman of the hospital, he said "we are very willing to do these things, is absolutely free, don't need to pay a penny. Without prejudice to the premise of consumer privacy, can do the work. My suggestion is that health development planning commission to lead in the past, I this special offer to the ministry of commerce, the ministry of commerce, please lead to do this. Pushing since I couldn't move, who planning commission the ministry of commerce, planning department, the people club department of health sector participation through a third party platform or on medical insurance card as the carrier to implement the three information sharing, is actually to hospitals, health care, medicine, break through three pieces. This medicine, the health administrative departments, feed the agency can enter this platform, actually also facilitate regulation.
The CPPCC national committee, renhe group chairman of the board Wen-long Yang:
Relevant statistics show that in 2020 May exceed the over-the-counter market in the United States in China, the market is very big, China is a big demand. National product of self-medication, characteristics and consumer's own choice, the current regulatory system is not fully reflect the characteristics of non-prescription drugs, over-the-counter and prescription management still vague, is basically unified, prescription and non-prescription drugs did not have a completely different management, non-prescription drugs registration, return include label instructions strictly, and prescribed drugs limits the innovation of non-prescription drugs, against the development of non-prescription drugs and participate in international competition.
Based on the above situation, it is suggested that according to China's implementation of drug classification management system and overall requirements, set up different from prescription and non-prescription drugs registration management system, mainly includes: a, according to the research characteristics of non-prescription drugs over-the-counter independent class; Second, making accord with the characteristics of non-prescription drugs registration approval requirements; Three, to set up the over-the-counter double wide transformation ways and technical guidelines; Four, in accordance with characteristics and encourage the brand construction of non-prescription drugs packaging labeling regulations.
▍ focus 6: health care
The National People's Congress, chongqing day SAN pharmaceutical group co., chairman of the board of directors of the company Liu:
Last year, I want some common medicine on national annual into health care, I see a lot of children's drugs into the health care this year, children's drugs why missing? Two reasons, one is that we did not have the bidding process for the children's drugs, all is very cheap, hospital no businessman also not production, lack of. Secondly, many no childfriendly medicine into the health care, in the breakthrough of reform in our country, the year before last year made children's drugs restore price adjustments, this also is a breakthrough, this year a lot of children's drugs into the health care, in fact our medical institutions in the use of children's drugs will not feel so scarce. But there's a problem, it is urgent rescue drug problem.
I have an idea on the reimbursement, should focus on solving the major disease insurance reimbursement, and on the hierarchical diagnosis and treatment, I support hierarchical diagnosis and treatment, but the classification diagnosis and treatment of major diseases for as long as it is turned up to be able to reimburse dramatically from 80% to 90%, we will break the. Hierarchical diagnosis is now in a small hospital was 80%, 90%, county hospital was 60%, 70%, city hospital were 20%, 30%, a push through system lead to grading diagnosis and treatment.
▍ focal point 7: two votes
The National People's Congress, chongqing day SAN pharmaceutical group co., chairman of the board of directors of the company Liu:
For drugs in public hospitals for two votes I don't feel any errors, support the national implementation of public medical institution of two votes, but the launch of two votes must be combined with drug bidding, in the process of correcting the problems existing in the bidding before, mainly cheap drugs urgent rescue drugs should pay more attention to the quality of the product, restore previous prices.
▍ focus 8: industry control
The National People's Congress, kahn pharmaceutical chairman Hu Jijiang:
How in the field of medicine and medicine to better play to the role of the market, and better play to the role of the government, the listed motion has a market value of nearly 300 billion that day, I wrote a sentence on the work diary, this is we do medicine industry person of shame, express although developing rapidly, but compared to the pharmaceutical industry, after all, it is a small industry, it can produce 300 billion market value of the company, we today the pharmaceutical industry's largest pharmaceutical companies only 115 billion of market value. What reason? Attention to, the relatively fast development of the rapid rise of the enterprise, industry, honestly is the government controls the least industry, the government doesn't even know how to pipe, such as the Internet industry, the government doesn't know how, just because the government doesn't know how to pipe, pipe of the very few, they developed rapidly, we precisely because the government too much medicine industry, tube a lot of things shouldn't tube, make this industry enterprises in day and night thinking about how to deal with the government's policy, the real study of market couldn't get on.
|
